Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

REVIEW ARTICLE

Geftinib

Gupta Ajay, Raina Vinod

Year : 2010| Volume: 6| Issue : 3 | Page no: 249-254

   This article has been cited by
 
1 Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report
Xue, X. and Xue, Q. and Liu, Y. and Pan, L. and Wang, K. and Zhang, L. and Wang, N. and Yang, B. and Wang, J.
Oncology Letters. 2013; 5(5): 1599-1600
[Pubmed]  [Google Scholar]
2 Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands
Verduyn, S.C. and Biesma, B. and Schramel, F.M.N.H. and van der Scheer, F.W. and Langenfeld, M.K. and de Peuter, M.A. and Dingemans, A.-M.C.
Health and Quality of Life Outcomes. 2012; 10(108)
[Pubmed]  [Google Scholar]
3 Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands
S Verduyn,Bonne Biesma,Franz MNH Schramel,Feike W van der Scheer,Merel K Langenfeld,Maria A de Peuter,Anne-Marie C Dingemans
Health and Quality of Life Outcomes. 2012; 10(1): 108
[Pubmed]  [Google Scholar] [DOI]
4 Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like cell resistance to EGFR-targeted inhibition
Clark, P.A., Iida, M., Treisman, D.M., Kalluri, H., Ezhilan, S., Zorniak, M., Wheeler, D.L., Kuo, J.S.
Neoplasia (United States). 2012; 14(5): 420-428
[Pubmed]  [Google Scholar]
5 Tumor control versus adverse events with targeted anticancer therapies
Keefe, D.M.K., Bateman, E.H.
Nature Reviews Clinical Oncology. 2012; 9(2): 98-109
[Pubmed]  [Google Scholar]
6 Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells
Bocci, G., Fioravanti, A., La Motta, C., Orlandi, P., Canu, B., Di Desidero, T., Mugnaini, L., (...), Danesi, R.
Biochemical Pharmacology. 2011; 81(11): 1309-1316
[Pubmed]  [Google Scholar]
7 Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells
Guido Bocci,Anna Fioravanti,Concettina La Motta,Paola Orlandi,Bastianina Canu,Teresa Di Desidero,Laura Mugnaini,Stefania Sartini,Sandro Cosconati,Rita Frati,Alessandro Antonelli,Piero Berti,Paolo Miccoli,Federico Da Settimo,Romano Danesi
Biochemical Pharmacology. 2011; 81(11): 1309
[Pubmed]  [Google Scholar] [DOI]
8 Tumor control versus adverse events with targeted anticancer therapies
Dorothy M. K. Keefe,Emma H. Bateman
Nature Reviews Clinical Oncology. 2011; 9(2): 98
[Pubmed]  [Google Scholar] [DOI]

 

Read this article